Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223047 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
252
Enrollment target
8
Study locations

NCT07223047 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 252 participants, below the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (11% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223047, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
252 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

Conditions Studied

Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC) Advanced Solid Malignancies

Interventions

  • DRUG Pembrolizumab
  • DRUG Cetuximab
  • DRUG Nab-Paclitaxel
  • DRUG Gemcitabine
  • DRUG BMS-986523

Study Locations (8)

Maryland

  • Local Institution - 0009 - Baltimore

Texas

  • NEXT Oncology - San Antonio

Utah

  • START Mountain Region - West Valley City

Virginia

  • NEXT Virginia - Fairfax

British Columbia

  • Local Institution - 0002 - Vancouver

Ontario

  • Local Institution - 0010 - Toronto

Barcelona [Barcelona]

  • Local Institution - 0006 - Badalona

Madrid

  • Local Institution - 0008 - Hortaleza

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2025-11-25
Est. Completion 2028-10-13
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07223047

The ClinicalTrials.gov registry entry for NCT07223047 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (11% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT07223047 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Maryland, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT07223047 about?

NCT07223047 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies". The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

What is the current status of trial NCT07223047?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2025-11-25. Estimated completion is 2028-10-13.

What conditions does trial NCT07223047 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Malignancies.

What interventions are being tested in trial NCT07223047?

The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), BMS-986523 (DRUG).

Who is sponsoring clinical trial NCT07223047?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223047 being conducted?

This trial has 8 study locations across Maryland, Texas, Utah, Virginia, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

Colorectal Cancer (CRC)

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.